Brief: Reviva Pharmaceuticals Announced Preclinical Efficacy Data On Brilaroxazine In Ipf, U.S. FDA Granted 'Orphan Drug' Designation

Reviva Pharmaceuticals Holdings

25/05/2023 11:26

May 25 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCED PRECLINICAL EFFICACY DATA
ON
BRILAROXAZINE IN IPF AT THE 2023 AMERICAN THORACIC SOCIETY
INTERNATIONAL CONFERENCE AND PUBLICATION IN MEDICAL RESEARCH
ARCHIVES
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - U.S. FDA HAS
GRANTED
ORPHAN DRUG DESIGNATION TO BRILAROXAZINE FOR IPF INDICATION
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - BELIEVES
BRILAROXAZINE
HAS POTENTIAL TO DELAY DISEASE PROGRESSION IN PAH AND IPF
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - INTENDS TO DEVELOP
BRILAROXAZINE FOR PULMONARY INDICATIONS

Source text for Eikon:  ID:nGNX9Xtq5F 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))